----------------------------------------------------
Sender: owner-e-drug@usa.healthnet.org
Precedence: bulk
Errors-To: owner-e-drug@usa.healthnet.org
Dears E-Druggers:
As mentioned in an earlier posting lysine-clonixinate (LC)
is marketed in Spain with the name of Dolalgial.
In 1994,the National Commission of Indicators of Quality of
prescription of the Spanish Ministry of Health evaluate LC
as drug of not intrinsic value which means efficacy and/or
safety not well established.
The only recently published clinical work about LC is:
Eberhardt R, et al. Analgesic efficacy and tolerability of
lysine-clonixinate versus ibuprofen in patients with
gonarthrosis. Curr Ther Res 1995; 56: 573-80.
A poor documentation for a broadly prescribed drug.
Vicente M.Asencio
Coordinator of the Regional Commission of
Quality Prescribing indicators
of the Andalusian Health Service(SAS)
Editor of Farm West
Apartado de correos 6135
29080 Malaga-Spain
Email:vicenteasencio@vnet.es
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.